Effects of programmed death receptor-1 antibody in patients with hepatitis B-associated liver cancer
10.3760/cma.j.cn501113-20210705-00317
- VernacularTitle:程序性死亡受体-1抗体对乙型肝炎相关肝癌患者乙型肝炎病毒的影响
- Author:
Yingying YU
1
;
Siyu WANG
;
Bo TU
;
Yingjuan SHEN
;
Qin QIU
;
Junqing LUAN
;
Fusheng WANG
;
Fanping MENG
;
Ming SHI
Author Information
1. 北京大学三○二临床医学院，北京 100039
- Keywords:
Hepatitis B virus;
Liver cancer;
Programmed death receptor-1;
Tyrosine kinase inhibitors;
Hepatitis B virus reactivation
- From:
Chinese Journal of Hepatology
2021;29(7):659-665
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of programmed death receptor (PD)-1 antibody therapy in patients with hepatitis B-associated liver cancer.Methods:Data of 29 chronically infected HBV patients with liver cancer who received PD-1 antibody combined with tyrosine kinase inhibitor in the Department of Infectious Diseases of the Fifth Medical Center of PLA General Hospital from March 2020 to January 2021 were selected. At the same time, all of the above-mentioned hepatitis B virus (HBV) patients were treated with nucleos(t)ide analogues. Patients clinical diagnostic data, laboratory test results, tumor response and the incidence of adverse reactions were collected retrospectively to understand the overall safety, therapeutic anti-tumor effect, HBV changes condition and the correlation between HBV changes and anti-tumor PD-1 antibody efficacy, high viral load treatment condition, and HBV reactivation safety issues. Statistical analysis was performed by non-parametric rank sum test.Results:Therapeutic anti-tumor effect and safety profile were good in patients. The complete remission rate was reached 27.6%. Adverse reactions were mostly mild, and the incidence of serious adverse reactions was low. After 12 weeks of follow-up, HBV DNA and hepatitis B surface antigen (HBsAg) was quantitatively decreased ( P < 0.05). HBV DNA and HBsAg were decreased more significantly in patients with progressive disease (PD), stable disease (SD) and partial response (PR) ( P < 0.05). Five patients with HBV DNA ≥ 10 4 IU/ml had responded well to the tumor treatment without serious adverse reactions. One patient had a slight increase in HBV DNA and alanine aminotransferase, while there was no HBV reactivation and correlated liver damage. Conclusion:Patients with HBV-associated liver cancer who received combined therapy have good anti-tumor efficacy and safety profile. PD-1 treatment has a certain effect on HBV. Compared with non-responders, patients with tumor response have better antiviral treatment efficacy. The safety of treatment in patients with high viral load is manageable, and there are no safety issues related to HBV reactivation.
